Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28586585 | 0.97 | ERN1 (0.44) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL248719 | 0.94 | ERN1 (0.50) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL650978 | 0.87 | ERN1 (0.50) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL29955962 | 0.82 | ERN1 (0.39) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL3070038 | 0.82 | ERN1 (0.39) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL29655114 | 0.82 | ERN1 (0.43) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL1972414 | 0.82 | TDP1 (0.41) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL31618920 | 0.82 | TDP1 (0.41) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL933374 | 0.82 | ERN1 (0.43) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL26292881 | 0.82 | ERN1 (0.39) | ERN1TDP1MEN1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707807-A | Preparation method and application of tacrine derivative | 沈阳药科大学 | 2025-03-28 | — | — | CN | claimed |
| CN-117143598-B | High-entropy carbon quantum dot nanomaterial and preparation method and application thereof | 中南大学 | 2024-11-08 | — | — | CN | claimed |
| CN-118459422-A | Thiazole thiazolinone compound containing multiple halogen atoms and preparation method thereof | 南京工业大学 | 2024-08-09 | — | — | CN | claimed |
| CN-118459420-A | Thiazolinone compound containing multiple halogen atoms and preparation method thereof | 南京工业大学 | 2024-08-09 | — | — | CN | claimed |
| CN-115611717-B | Preparation method of polyfluorobenzaldehyde | 上海万溯药业有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-117143598-A | High-entropy carbon quantum dot nanomaterial and preparation method and application thereof | 中南大学 | 2023-12-01 | — | — | CN | claimed |
| CN-116178121-A | Preparation method of 2,4, 5-trifluoro-benzaldehyde | 浙江巍华新材料股份有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-115677477-B | Preparation method of 2,4, 5-trifluoro-phenylacetic acid and intermediate thereof | 上海康鹏科技股份有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-115677477-A | Preparation method of 2,4, 5-trifluoro-phenylacetic acid and intermediate thereof | 上海康鹏科技股份有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-115611717-A | Preparation method of polyfluorobenzaldehyde | 上海万溯药业有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-103819475-A | Synthetic method of sitagliptin and salt thereof | ZHEJIANG NHU CO LTD | 2014-05-28 | — | — | CN | claimed |
| CN-103483340-A | Synthetic method for sitagliptin | WUXI BIORTUS BIOSCIENCES CO LTD | 2014-01-01 | — | — | CN | claimed |
| EP-1472215-A4 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-05-09 | — | — | EP | claimed |
| US-6949574-B2 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | claimed |
| EP-1472215-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-11-03 | — | — | EP | claimed |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2003-10-16 | — | — | US | claimed |
| WO-2003065989-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-14 | — | — | WO | claimed |
| EP-0725787-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1996006853-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-03-07 | — | — | WO | claimed |
| EP-0164619-B1 | 2,4,5-TRIHALO OR 2,3,4,5-TETRAHALO BENZENE DERIVATIVES AND PROCESS FOR PRODUCING THEM | BAYER AG (DE) | 1988-10-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | ERN1 4398/4885TDP1 949/4885MEN1 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.